A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours
UPDATE 4th July 2026. From a presentation at SNMII 2026 "New prospective comparative research suggests that the PET/CT radiopharmaceutical 64Cu-SARTATE may offer significant advantages over 68Ga-DOTATATE for detecting liver foci in patients with known or suspected neuroendocrine tumors (NETs)" click here UPDATE 23rd December 2025. (Originally published Apr 2021). Phase 3 trial in discussion (clinical trials reference detail to follow) Sydney, Australia 22 December 2025 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce it will be commencing a pivotal Phase III…